Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Invivyd, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Biological Products, (No Diagnostic Substances)
No intraday reading yet this session.
Invivyd, Inc. has 6 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Invivyd, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Three specialty distributors accounted for 46%, 23% and 17% of total gross sales for the year ended December 31, 2025.”
$25M relationship
basisIVVD fy2025 · closed 2025-12 $53M
FILING10-K0001193125-26-092547cik 0001832038
“Sales to the 3PL Agent accounted for 19% and three specialty distributors accounted for 42%, 24% and 13% of total gross sales for the year ended December 31, 2024.”
$22M relationship
basisIVVD fy2025 · closed 2025-12 $53M
FILING10-K0000950170-25-042332cik 0001832038
“Sales to the 3PL Agent accounted for 19% and three specialty distributors accounted for 42%, 24% and 13% of total gross sales for the year ended December 31, 2024.”
$10M relationship
basisIVVD fy2025 · closed 2025-12 $53M
FILING10-K0000950170-25-042332cik 0001832038
“On April 18, 2025 (the "Closing Date"), we entered into that certain Loan and Security Agreement (the "Loan Agreement") with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, as lender (the "Lender"), that provides for a senior secured term loan facility in an aggregate principal amount of up to $30 million (the "Term Facility") consisting of: (a) Term A Loans in an aggregate principal amount of up to $10 million, which shall be available to be drawn from and after August 15, 2025 through December 31, 2026 upon compliance with certain financial covenants and conditions; (b) Term B Loans in an aggregate principal amount of up to $10 million, which shall be available to be drawn during the period commencing on the date of the achievement of certain net product revenue milestones and ending on June 30, 2027; and (c) Term C Loans in an aggregate principal amount of up to $10 million, which shall be available to be drawn during the period commencing on the date of the achievement of certain net product revenue milestones and ending on June 30, 2027 (collectively, the "Term Loans").”
FILING10-K0001193125-26-092547cik 0001832038
“We are party to the Adimab Assignment Agreement with Adimab, under which Adimab has assigned to us its rights, title and interest in and to certain of its coronavirus-specific antibodies, including modified or derivative forms thereof, and related intellectual property.”
FILING10-K0000950170-25-042332cik 0001832038
“In December 2023, we entered into a Controlled Equity Offering SM Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co., as sales agent ("Cantor"), pursuant to which we may, at our option, offer and sell up to an aggregate amount of $75.0 million of our common stock, through Cantor, acting as sales agent.”
FILING10-K0000950170-25-042332cik 0001832038
“We have engaged WuXi Biologics, a CDMO, for the development and manufacture of our product candidates for clinical and commercial use.”
FILING10-K0000950170-25-042332cik 0001832038
“We have contracted with WuXi Biologics for the manufacturing of commercial-scale PEMGARDA and VYD2311.”
FILING10-K0000950170-25-042332cik 0001832038
“In November 2022 (the "PHP Effective Date"), we entered into a Master Services Agreement with Population Health Partners, L.P. ("PHP"), pursuant to which PHP agreed to provide services and create deliverables for us as agreed between us and PHP and set forth in one or more work orders under such agreement (the "PHP MSA").”
FILING10-K0000950170-25-042332cik 0001832038
“Under the license agreement, we will provide Biocon materials and know-how to manufacture and commercialize an antibody treatment based on adintrevimab in India and select emerging markets.”
FILING10-K0000950170-25-042332cik 0001832038
“In order to enable us to execute sales in the U.S. prior to obtaining such licenses, we and an affiliate of the 3PL Agent (the "Title Company") entered into a Temporary Title Model Agreement (the "Temporary Title Model Agreement"), which was an amendment to the 3PL Agreement, so that the Title Company could purchase and take title to the product and sell the product to the specialty distributors who contracted to purchase the product from us.”
FILING10-K0000950170-25-042332cik 0001832038
Watchlist prices, news filtered to it, and its next report on your desk.
IVVD (Invivyd, Inc.) has 6 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.